Polo-like Kinase (PLK)

Polo-like Kinase (PLK) Related Products (44):

By Effects:	Inhibitors (41) Degrader (1)

Cat. No.	Product Name	Effect	Purity

HY-112356

Scytonemin	Inhibitor	99.53%
Scytonemin is a hydrophobic alkaloid pigment that can be isolated from the outer sheath of cyanobacteria. Scytonemin has protective function against short-wave solar ultraviolet (UV) radiation, which can reduce the generation of reactive oxygen species (ROS) and the formation of DNA damage. Scytonemin also has anti-inflammatory and anti-proliferative activities, produces concentration-dependent inhibition (IC₅₀=2.0 μM) of polo-like kinase 1 (PLK1)-mediated cdc25C phosphorylation, and plays an important role in regulating the G2/M transition in the cell cycle. It can be used in the research of cancer, acute inflammation and sunscreen cosmetics.

HY-102069

3MB-PP1	Inhibitor	99.66%
3MB-PP1, a bulky purine analog, is a Polo-like kinase 1 (Plk1) inhibitor. 3MB-PP1 blocks mitotic progression and cell division arise through target Plk1 in in cells expressing analog-sensitive Plk1 alleles. 3MB-PP1 specifically inhibits the activity of analog-sensitive Ssn3 (Cdk8). 3MB-PP1 inhibits Leu93 Mutant Zipper-interacting protein kinase (Leu93-ZIPK; IC₅₀=2 μM). 3MB-PP1 can be used for the research of hypha formation of Candida albicans and cell division.

HY-75578

dTAG Targeting Ligand 1	Inhibitor
dTAG Targeting Ligand 1 (SUBSTITUTE SHEET 245) is a PROTAC target protein ligand (Ligand for Target Protein for PROTAC). dTAG Targeting Ligand 1 can be used for synthesis PROTACs.

HY-123467

Lasiokaurin	Inhibitor	99.68%
Lasiokaurin is a diterpenoid compound isolated from Isodon lasiocarpus.

HY-13647

HMN-176	Inhibitor	98.84%
HMN-176 is a stilbene derivative which inhibits mitosis, interfering with polo-like kinase-1 (plk1), without significant effect on tubulin polymerization.

HY-176734

CZL-S092	Inhibitor
CZL-S092 is a PLK4 inhibitor with an IC₅₀ value of 0.9 nM and excellent selectivity over other PLK4 family members (PLK1, PLK2, and PLK3).CZL-S092 exhibits anti-neuroblastoma activity in vitro (IMR-32 cells, IC₅₀ = 1.143 μM) and acceptable oral bioavailability in vivo (SD rats, F = 22.1%). CZL-S092 can be used in studies of various cancers including neuroblastoma cancer.

HY-172943

PLK1/PRC1-IN-1	Inhibitor
PLK1/PRC1-IN-1 (compound B4) is a PLK1/PRC1 protein complex formation inhibitor. PLK1/PRC1-IN-1 can be used in the study of non-small cell lung cancer (NSCLC) .

HY-164955

TTK/PLK1-IN-1	Inhibitor
TTK/PLK1-IN-1 (Formula I) is the inhibitor for threonine tyrosine kinase (TTK) and polo-like kinase 1 (PLK1) with IC₅₀ of 7 nM and 72 nM. TTK/PLK1-IN-1 regulates spindle assembly checkpoint (SAC), and exhibits antitumor efficacy against TNBC.

HY-151971

Aurora kinase-IN-3	Inhibitor	98.47%
Aurora kinase-IN-3 (Compound 15a) is an orally active AURKB inhibitor that elicits an AURKB-suppressive activity by disrupting the mitotic localization of AURKB, rather than inhibiting its phosphorylation of H3 at Ser10.

HY-159493

BI2536-PEG2-Halo	Inhibitor	99.44%
BI2536-PEG2-Halo is a bifunctional molecule containing a ligand for Halo tag and a Polo-like kinase 1 (PLK1) inhibitor BI-2536 (HY-50698). BI2536-PEG2-Halo inhibits the proliferation of 293T cells with Halo-p53R273H(FL)-mCherry tag (IC₅₀=23 nM), exhibits selective toxicity against p53 mutant cancer cells.

HY-13994

Mps1-IN-2	Inhibitor	98.08%
Mps1-IN-2 is a potent, selective and ATP-competitive dual Mps1/Plk1 inhibitor, with an IC₅₀ and a K_d of 145 nM and 12 nM for Mps1 and a K_d of 61 nM for Plk1.

HY-149324

SP27	Degrader	99.21%
SP27 is a PROTAC that can selective degrades PLK4, with a DC₅₀ of 19.5 nM. SP27 can be used for the research of breast cancer.

HY-126249

AAPK-25	Inhibitor	98.31%
AAPK-25 is a potent and selective Aurora/PLK dual inhibitor with anti-tumor activity, which can cause mitotic delay and arrest cells in a prometaphase, reflecting by the biomarker histone H3^Ser10 phosphorylation and followed by a surge in apoptosis. AAPK-25 targets Aurora-A, -B, and -C with K_d values ranging from 23-289 nM, as well as PLK-1, -2, and -3 with K_d values ranging from 55-456 nM.

HY-134775

PLK4-IN-1	Inhibitor	99.94%
PLK4-IN-1 (Example A6) is a PLK4 inhibitor, with an IC₅₀ of ≤ 0.1 μM.

HY-117291A

XMD-17-51 TFA		99.46%
XMD-17-51 TFA is a pyrimido-diazepinone compound that is able to modulate protein kinases.

HY-10197R

Wortmannin (Standard)	Inhibitor
Wortmannin (Standard) is the analytical standard of Wortmannin. This product is intended for research and analytical applications. Wortmannin (SL-2052; KY-12420) is a potent, selective and irreversible PI3K inhibitor with an IC50 of 3 nM. Wortmannin also blocks autophagy formation, and potently inhibits Polo-like kinase 1 (PlK1) and Plk3 with IC50s of 5.8 and 48 nM, respectively.

HY-RS10721

Plk4 Mouse Pre-designed siRNA Set A	Inhibitor
Plk4 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Plk4 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS10715

Plk2 Mouse Pre-designed siRNA Set A	Inhibitor
Plk2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Plk2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-155377

PLK1/p38γ-IN-1	Inhibitor
PLK1/p38γ-IN-1(compound 14) is a multitarget inhibitors ofPLK1andp38γ. PLK1/p38γ-IN-1inhibits the growth of human hepatocellular carcinoma and hepatoblastoma cells in vitro.

HY-RS10720

PLK4 Human Pre-designed siRNA Set A	Inhibitor
PLK4 Human Pre-designed siRNA Set A contains three designed siRNAs for PLK4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Name
Email *

	Sorry, but the email address you supplied was invalid.